Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson Q4 Profit Decreases
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Bears Hire Ben Johnson
Detroit Lions fans crush Ben Johnson for leaving to Chicago Bears: 'Benedict Johnson'
Some Detroit Lions fans are beside themselves that Ben Johnson is staying in the NFC North with the Chicago Bears: 'Benedict Johnson'
Ben Johnson agrees to become Bears head coach
Detroit Lions offensive coordinator Ben Johnson has agreed to become the Chicago Bears head coach, a person familiar with the situation told The Associated Press Ben Johnson helped Jared Goff establish himself as one of the NFL’s top quarterbacks.
Ben Johnson's 3 most important hires on Bears coaching staff
Now that the head coaching search is over, the actual work begins. The roster needs improving, but it is also very important for the team to make great hires for the rest of the coaching staff. Johnson will certainly be the head decision-maker when it comes to building his group of coaches.
3h
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
1h
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
MassDevice
4h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
21h
on MSN
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
5h
Johnson & Johnson reports Q4 adjusted EPS $2.04, consensus $2.02
Reports Q4 revenue $22.5B, consensus $22.45B. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an ...
4h
on MSN
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
MarketBeat on MSN
5d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
5d
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback